New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
NCT ID NCT06390995
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to deliver chemotherapy directly to cancer cells. The trial has two parts: Phase 1 checks for side effects and the best dose, and Phase 2 measures how well the drug shrinks tumors. About 28 participants will receive the drug every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
-
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan
-
Chiba University Hospital
Chiba, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
-
Hyogo Cancer Center
Akashi, Hyōgo, Japan
-
Iwate Medical University Hospital
Shiwa-gun, Iwate, Japan
-
Jikei University Kashiwa Hospital
Kashiwa, Chiba, Japan
-
Keio University Hospital
Shinjuku-ku, Tokyo, Japan
-
Kurume University Hospital
Kurume, Fukuoka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
-
Okayama University Hospital
Okayama, Japan
-
Osaka International Cancer Institute
Osaka, Japan
-
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
-
Sapporo Medical University Hospital
Sapporo, Hokkaido, Japan
-
Shikoku Cancer Center
Matsuyama, Ehime, Japan
-
Shizuoka Cancer Center
Nakatogari, Shizuoka, Japan
-
The Jikei University Hospital
Minato-ku, Tokyo, Japan
-
Tohoku University Hospital
Sendai, Miyagi, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirvetuximab soravtansine (a drug that targets a protein called folate receptor alpha on cancer cells and delivers a chemotherapy agent)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with advanced ovarian cancer or other solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to all patients. Side effects, including eye problems and nerve damage, are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.